Publication — IRIC

YES, a novel therapeutic target in hepatocellular carcinoma.

Identification of dominant, actionable oncogenic signaling pathways is key to guide the development of new targeted treatments for advanced-stage hepatocellular carcinoma (HCC). We have recently unveiled a novel YES-YAP/TAZ signaling axis involved in liver cancer development. Our study identifies the tyrosine kinase YES as a potential therapeutic target in HCC.

Date de publication
1er mai 2022
Lapouge M, Meloche S
Référence PubMed
Mol Cell Oncol 2022;9(1):2069993
ID PubMed
Signaling and Cell Growth Laboratory, Institute for Research in Immunology and Cancer, Montreal, Quebec, Canada.